Abstracts tagged "Antiphospholipid antibodies and systemic lupus erythematosus (SLE)"

Abstract Number: 2629 • 2018 ACR/ARHP Annual Meeting
Longitudinal Analysis of Persistent Positivity of Antiphospholipid Antibodies in Systemic Lupus Erythematosus
Michelle Petri¹, Mertcan Avci² and Laurence S Magder³, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey, ³Epidemiology and Preventive Medicine, University of MD, Baltimore, MD
Background/Purpose: ‘Persistent positivity” has been a part of laboratory criteria for antiphospholipid syndrome classification criteria and requires two positive tests. We investigated the clinical utility…
Abstract Number: 703 • 2017 ACR/ARHP Annual Meeting
Clinical Value of Autoantibodies for Lupus Myelitis and Its Subtypes: A Systematic Review
Hiroshi Oiwa¹, Akira Kuriyama², Tomoyasu Matsubara³ and Eiji Sugiyama⁴, ¹Rheumatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan, ²General Medicine, Kurashiki Central Hospital, Kurashiki, Japan, ³Neurology, Hiroshima University Hospital, Hiroshima, Japan, ⁴Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: We conducted a systematic review to investigate the clinical value of clinical characteristics and autoantibodies, especially lupus-specific antibodies, for lupus myelitis and its subtypes.…
Abstract Number: 2188 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies and the Risk of Damage Accrual in Systemic Lupus Erythematosus
Mara Taraborelli¹, Laura Leuenberger², Maria Grazia Lazzaroni³, Nicole Martinazzi³, Wei Zhang⁴, Jane E. Salmon², Franco Franceschini¹, Angela Tincani³ and Doruk Erkan², ¹Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁴Healthcare Research Institute, Hospital for Special Surgery, New York, NY
Background/Purpose: A limited number of studies evaluated the impact of antiphospholipid antibodies (aPL) on organ damage in Systemic Lupus Erythematosus (SLE) with contrasting conclusions. The…
Abstract Number: 2202 • 2015 ACR/ARHP Annual Meeting
Different Patterns of Positivity for IgG Anti-Cardiolipin, Anti-Beta-2-Glycoprotein I and Anti-Domain I Antibodies within the First Year of Disease in 501 Patients with SLE – Associations with Different Clinical Outcomes
Amrita D'Souza¹, Charis Pericleous², Oliver Leach¹, Karim Fouad Alber¹, Thomas McDonnell², Yiannis Ioannou², Ian Giles³, David A. Isenberg⁴ and Anisur Rahman⁵, ¹Centre for Rheumatology Research, University College London, London, United Kingdom, ²Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ³Rayne Intitiute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ⁴Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁵Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom
Background/Purpose: Antiphospholipid Syndrome (APS) is an autoimmune rheumatic disorder in which antiphospholipid antibodies (aPL) cause clinical sequelae including vascular events (VE) and pregnancy morbidity (PM).…
Abstract Number: 18 • 2014 ACR/ARHP Annual Meeting
The Effect of Clinically Significant Antiphospholipid Antibody Positivity on Organ Damage in Systemic Lupus Erythematosus
Mara Taraborelli¹, Laura Leuenberger², Wei Zhang³, Angela Tincani¹, Jane Salmon² and Doruk Erkan², ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Healthcare Research Institute, Hospital for Special Surgery, New York, NY
Background/Purpose: The effect of antiphospholipid antibodies (aPL) on organ damage in Systemic Lupus Erythematosus (SLE) patients remains unclear as there are limited number of studies…
Abstract Number: 3 • 2014 ACR/ARHP Annual Meeting
Is There an Association Between Persistently High Positive Antiphospholipid Antibody Profile and Organ Damage Accrual in Lupus Patients?
Doruk Erkan¹, Lisa G. Criscione-Schreiber², Maria Dall'era³, Olga Dvorkina⁴, Russell Griffin⁵, Galina Marder⁶, Maureen A. McMahon⁷, Jorge Sanchez-Guerrero⁸, Amit Saxena⁹ and Robert Roubey¹⁰, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Dept of Med/Rheum Div, Duke University School of Medicine, Durham, NC, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Medicine, SUNY Health Science Center at Brooklyn, Brooklyn, NY, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, North Shore Long Island Health System, Great Neck, NY, ⁷Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁸UHN Toronto Western Hospital, Toronto, ON, Canada, ⁹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ¹⁰Division of Rheumatology and Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Few studies assessed the impact of antiphospholipid antibodies (aPL) on organ damage in lupus with conflicting results. Our objective was to determine if persistently…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].